Dexcom Inc
DXCM66.060USD
+0.150+0.23%
Handelsschluss 12/19, 16:00（ET）Kurse um 15 Minuten verzögert
25.76BMarktkapitalisierung
35.86KGV TTM
mehr Informationen über Dexcom Inc Unternehmen
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Dexcom Inc Informationen
BörsenkürzelDXCM
Name des UnternehmensDexcom Inc
IPO-datumApr 14, 2005
CEOMr. Jacob Steven (Jake) Leach
Anzahl der mitarbeiter10300
WertpapierartOrdinary Share
GeschäftsjahresendeApr 14
Addresse6340 Sequence Drive
StadtSAN DIEGO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92121
Telefon18582000200
Websitehttps://www.dexcom.com/
BörsenkürzelDXCM
IPO-datumApr 14, 2005
CEOMr. Jacob Steven (Jake) Leach
Führungskräfte von Dexcom Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jacob Steven (Jake) Leach
Mr. Jacob Steven (Jake) Leach
President, Interim Principal Executive Officer, Chief Operating Officer, Director
President, Interim Principal Executive Officer, Chief Operating Officer, Director
294.46K
+6.59%
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Interim Independent Chairman of the Board
Interim Independent Chairman of the Board
62.13K
+4.65%
Mr. Steven R. (Steve) Altman
Mr. Steven R. (Steve) Altman
Independent Director
Independent Director
61.05K
+4.13%
Mr. Richard Alexander Collins
Mr. Richard Alexander Collins
Independent Director
Independent Director
44.38K
+5.82%
Mr. Nicholas (Nick) Augustinos
Mr. Nicholas (Nick) Augustinos
Independent Director
Independent Director
42.13K
+6.12%
Mr. Jereme M. Sylvain
Mr. Jereme M. Sylvain
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
35.33K
-12.01%
Ms. Bridgette P. Heller
Ms. Bridgette P. Heller
Independent Director
Independent Director
27.03K
-3.61%
Mr. Kyle Malady
Mr. Kyle Malady
Independent Director
Independent Director
22.67K
-2.86%
Ms. Rimma Driscoll
Ms. Rimma Driscoll
Independent Director
Independent Director
9.04K
+127.87%
Ms. Renee D. Gala
Ms. Renee D. Gala
Independent Director
Independent Director
6.88K
+20.30%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jacob Steven (Jake) Leach
Mr. Jacob Steven (Jake) Leach
President, Interim Principal Executive Officer, Chief Operating Officer, Director
President, Interim Principal Executive Officer, Chief Operating Officer, Director
294.46K
+6.59%
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Interim Independent Chairman of the Board
Interim Independent Chairman of the Board
62.13K
+4.65%
Mr. Steven R. (Steve) Altman
Mr. Steven R. (Steve) Altman
Independent Director
Independent Director
61.05K
+4.13%
Mr. Richard Alexander Collins
Mr. Richard Alexander Collins
Independent Director
Independent Director
44.38K
+5.82%
Mr. Nicholas (Nick) Augustinos
Mr. Nicholas (Nick) Augustinos
Independent Director
Independent Director
42.13K
+6.12%
Mr. Jereme M. Sylvain
Mr. Jereme M. Sylvain
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
35.33K
-12.01%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Distributor
977.80M
84.50%
Direct
179.30M
15.50%
Nach RegionUSD
Name
Umsatz
Anteil
United States
841.00M
72.68%
Outside of United states
316.10M
27.32%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Distributor
977.80M
84.50%
Direct
179.30M
15.50%
Aktionärsstatistik
Aktualisiert: Tue, Nov 18
Aktualisiert: Tue, Nov 18
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
12.63%
BlackRock Institutional Trust Company, N.A.
6.24%
State Street Investment Management (US)
4.32%
Baillie Gifford & Co.
4.07%
Geode Capital Management, L.L.C.
2.81%
Andere
69.92%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
12.63%
BlackRock Institutional Trust Company, N.A.
6.24%
State Street Investment Management (US)
4.32%
Baillie Gifford & Co.
4.07%
Geode Capital Management, L.L.C.
2.81%
Andere
69.92%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
53.37%
Investment Advisor/Hedge Fund
28.82%
Hedge Fund
7.32%
Research Firm
4.05%
Pension Fund
2.14%
Bank and Trust
1.94%
Sovereign Wealth Fund
1.61%
Venture Capital
0.48%
Individual Investor
0.37%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
2120
388.08M
103.93%
+205.32K
2025Q3
2198
388.02M
104.56%
+4.65M
2025Q2
2236
383.14M
106.39%
+1.38M
2025Q1
2227
382.03M
104.52%
-27.81M
2024Q4
2209
376.25M
104.20%
-2.27M
2024Q3
2125
380.57M
105.64%
-16.02M
2024Q2
2097
395.55M
99.88%
+7.96M
2024Q1
2075
388.09M
102.93%
-19.55M
2023Q4
2061
396.17M
102.99%
+6.26M
2023Q3
1969
388.25M
103.58%
-414.67K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
48.15M
12.28%
+859.71K
+1.82%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
24.25M
6.18%
-475.12K
-1.92%
Jun 30, 2025
State Street Investment Management (US)
16.86M
4.3%
+175.27K
+1.05%
Jun 30, 2025
Baillie Gifford & Co.
16.71M
4.26%
+2.53M
+17.81%
Jun 30, 2025
Geode Capital Management, L.L.C.
10.77M
2.75%
+358.62K
+3.45%
Jun 30, 2025
Jennison Associates LLC
11.52M
2.94%
+994.30K
+9.45%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
8.03M
2.05%
-28.35K
-0.35%
Aug 31, 2025
Nuveen LLC
7.30M
1.86%
-549.07K
-7.00%
Jun 30, 2025
MFS Investment Management
6.49M
1.65%
+3.30M
+103.55%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
Global X Internet of Things ETF
3.86%
iShares U.S. Medical Devices ETF
2.71%
Motley Fool Global Opportunities ETF
1.9%
First Trust Growth Strength ETF
1.74%
Putnam Sustainable Future ETF
1.61%
First Trust NASDAQ-100 Ex-Technology Sector Index Fund
1.51%
Invesco S&P 500 Equal Weight Health Care ETF
1.25%
Direxion NASDAQ-100 Equal Weighted Index Shares
0.83%
First Trust NASDAQ 100 Equal Weighted Index Fund
0.83%
iShares Russell Mid-Cap Growth ETF
0.7%
Mehr Anzeigen
Global X Internet of Things ETF
Anteil3.86%
iShares U.S. Medical Devices ETF
Anteil2.71%
Motley Fool Global Opportunities ETF
Anteil1.9%
First Trust Growth Strength ETF
Anteil1.74%
Putnam Sustainable Future ETF
Anteil1.61%
First Trust NASDAQ-100 Ex-Technology Sector Index Fund
Anteil1.51%
Invesco S&P 500 Equal Weight Health Care ETF
Anteil1.25%
Direxion NASDAQ-100 Equal Weighted Index Shares
Anteil0.83%
First Trust NASDAQ 100 Equal Weighted Index Fund
Anteil0.83%
iShares Russell Mid-Cap Growth ETF
Anteil0.7%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Mar 28, 2022
Split
1→4
Datum
Art
Verhältnis
Mar 28, 2022
Split
1→4
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Dexcom Inc?
Die fünf größten Anteilseigner von Dexcom Inc sind:
The Vanguard Group, Inc. hält 48.15M Aktien, was 12.28% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 24.25M Aktien, was 6.18% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 16.86M Aktien, was 4.30% der Gesamtaktien entspricht.
Baillie Gifford & Co. hält 16.71M Aktien, was 4.26% der Gesamtaktien entspricht.
Geode Capital Management, L.L.C. hält 10.77M Aktien, was 2.75% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 48.15M Aktien, was 12.28% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 24.25M Aktien, was 6.18% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 16.86M Aktien, was 4.30% der Gesamtaktien entspricht.
Baillie Gifford & Co. hält 16.71M Aktien, was 4.26% der Gesamtaktien entspricht.
Geode Capital Management, L.L.C. hält 10.77M Aktien, was 2.75% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Dexcom Inc?
Die drei wichtigsten Anteilseigner-Typen von Dexcom Inc sind:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Wie viele Institutionen halten Anteile an Dexcom Inc (DXCM)?
Mit Stand vom 2025Q4 halten 2120 Institutionen Anteile an Dexcom Inc, mit einem Gesamtmarktwert von etwa 388.08M, was 103.93% der Gesamtanteile entspricht. Im Vergleich zum 2025Q3 ist der institutionelle Aktienbesitz um -0.63% gestiegen.
Was ist die größte Einnahmequelle von Dexcom Inc?
Am FY2025Q2 erzielte das Geschäft mit Distributor für Dexcom Inc den höchsten Umsatz in Höhe von 977.80M, was 84.50% des Gesamtumsatzes entspricht.
